Migraine – Launch of new molecules to further enhance treatment opportunities

28 Feb 2018 • by Natalie Aster

Migraine is a neurological disorder which is often characterized by moderate to severe pain on one side of the head. Migraine attacks can be very intimidating and vary in range and frequency for different patients.

Migraine is known to be one of the three most prevalent diseases in the world. As per the latest report of Pharmascroll, "Migraine- A Detailed overview", the disease is prevalent in around 14% of the entire world population. In the US, the prevalence of Migraine is around 12% of the US population.

There are a range of medications available for Migraine starting from Acute to Prophylactic treatment therapies. Majority of the Migraine patients rely on these medications to relieve themselves of the throbbing pain experienced during the Migraine and to reduce the frequency of occurrence of Migraine attacks.

As per the current scenario in Migraine indication, the Acute therapies capture the majority share of Migraine treated patients. However, the approval and launch of new anti CGRP molecules is expected to shift the momentum towards preventive treatments. There are four major anti CGRP preventive therapies expected to be launched in coming 2-3 years. These include Erenumab by Novartis, Fremanezumab by Teva, Galcanezumab by Lilly and Eptinezumab by Alber. The latest report available at www.pharmascroll.com/product/migraine-detailed- overview indicates that 3 out of 4 anti CGRP molecules are expected to do a sales revenue close to $3 Bn at their peak. The pipeline for Acute Migraine treatments also looks strong with the expected launch of many pipeline molecules including Ubrogepant, Semprana and Lasmiditan.

The report provides an overview of Migraine in detail, highlights the Migraine epidemiology split into Episodic and Chronic Migraine in the key geographies, elaborates on the drugs prescribed and expected to be prescribed in Migraine and covers the detailed market sizing drug wise and country wise in value sales and patient numbers along with forecasts. The drugs included in the sales and patients forecast are Fremanezumab, Erenumab, Galcanezumab, Eptinezumab, Ubrogepant, Lasmiditan, Semprana, Relpax, Botox and only the sales for these products in Migraine indication is included in the forecast.

Why Migraine Headaches should never be ignored

Migraine is a neurological disorder which is often characterized by moderate to severe pain on one side of the head. Migraine headaches are often linked to a throbbing pain which is also pulsating in nature. Migraine attacks, often in many patients, are accompanied or preceded by certain sensory signs and symptoms such as vomiting, nausea, increased sensitivity to light and sound etc.

Migraine attacks can be very intimidating and vary in range and frequency for different patients. A typical Migraine attack in a patient can last starting from a few hours to a multiple number of days depending on type and intensity of Migraine in a patient. The range of time of the Migraine attack is also impacted and characterized by a buildup phase which is also called pre-monitory phase and a postdrome phase and hence the Migraine attack can range for few days even if the pain experienced by the patient is for a lesser period.

The frequency of the Migraine attacks also varies for different patients. While some of the patients might experience Migraine attacks very infrequently during a typical month, other patients might experience Migraine attacks almost every day or every alternate day. The life of the patients experiencing Migraine attacks very frequently or for more than 15 days in a month is most impacted and many of these patients are typically cut off from the social world and avoid interactions with other people.

Migraine is known to be one of the three most prevalent diseases in the world and the disease is prevalent in around 14% of the entire world population. In the US, the prevalence of Migraine is around 12% of the US population. Migraine is more prevalent in women and impacts the women 3 times more as compared to men which comes down to affecting around one in every five women across the globe.

Migraine can impact the quality of life of a patient to a great extent. The Migraine patients are usually debilitated and frustrated most of the times. It has been observed that the Migraine patients usually try to hide their condition from the outside world because of the fear of being ignored and hence try to cut off their social life and interactions pushing themselves in the world of loneliness. Also, the Migraine patients are not able to complete their tasks with complete productivity and hence are forced to miss offices and schools leading to a negative impact on their work lives and professional careers. Also, in most of the cases, the Migraine patients are not able to do their daily tasks which otherwise they could have done with ease leading to disability in the majority of the patients. All these factors, in turn, lead to social as well as the economic burden on the patients wherein the patients have to spend a lot on the treatment of Migraine as well as earn less due to the loss of productivity at work.

Thus, Migraine can have physical, social and economic impact on the patients and can lead to greater troubles and loneliness in the lives of people. Hence Migraine headaches need to be very well differentiated with the other forms of headaches and need to be addressed by specialists as early as possible.

Visit Pharmascroll Research and Consulting online page at MarketPublishers.com to find many other research reports prepared by this publisher.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com 
MarketPublishers.com